Helicobacter pylori eradication as a gastroprotective strategy in elderly aspirin-treated subjects: established facts and unanswered questions
- PMID: 36638779
- DOI: 10.1093/eurheartj/ehac808
Helicobacter pylori eradication as a gastroprotective strategy in elderly aspirin-treated subjects: established facts and unanswered questions
Conflict of interest statement
Conflict of interest: G.L. received grant support (to the Institution) for investigator-initiated research from American Heart Association, Italian National Health Service, and Italian Minister of Education, University and Research. She is currently involved in the Research Programs of the Italian Cardiovascular Network. She received personal fees from Astra Zeneca, Boehringer Ingelheim, Novo Nordisk, Daiichi Sankyo, Sanofi, and Novartis. C.P. received consultant and speaker fees from Acticor Biotech, Amgen, Bayer, GlaxoSmithKline, Tremeau, Zambon, and grant support (to the Institution) for investigator-initiated research from AIFA (Italian Drug Agency), Bayer, Cancer Research UK and European Commission; he chairs the Scientific Advisory Board of the International Aspirin Foundation.
Comment on
-
Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial.Lancet. 2022 Nov 5;400(10363):1597-1606. doi: 10.1016/S0140-6736(22)01843-8. Lancet. 2022. PMID: 36335970 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical